Brief: Voyager Therapeutics Inc Announces Selection Of Development Candidate For SOD1 Amyotrophic Lateral Sclerosis Gene Therapy Program
06/12/2023 12:06
Dec 6 (Reuters) - Voyager Therapeutics Inc VYGR.O :
* VOYAGER THERAPEUTICS INC - ANNOUNCES SELECTION OF
DEVELOPMENT
CANDIDATE FOR SOD1 AMYOTROPHIC LATERAL SCLEROSIS GENE THERAPY
PROGRAM
* VOYAGER THERAPEUTICS INC - IND FILING EXPECTED IN MID-2025
Source text for Eikon: ID:
Further company coverage: VYGR.O
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Voyager Therapeutics
See all newsBrief: Voyager Names Robin Swartz As President; Expected To Succeed As CEO In Q1 2027
Voyager Therapeutics, Inc. reports results for the quarter ended June 30 - Earnings Summary
Voyager Therapeutics Q2 collaboration revenue falls, net loss narrows
Brief: Voyager Therapeutics Q2 Net Income USD -24.473 Million
Voyager Therapeutics Inc expected to post a loss of 48 cents a share - Earnings Preview